Evidence map›Paper›PMID 40900796›Full record

ArticleFrontiers in oncology2025

2-Deoxy-D-Glucose and ES-936 sensitize cancer- but not normal cells to both low- and high LET irradiation.

Katja Kratz, Henrieke Förster, Kira Vogel, Marco Durante, Burkhard Jakob

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Katja KratzDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany.
Henrieke FörsterDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany.
Kira VogelDepartment of Biology, Technical University of Darmstadt, Darmstadt, Germany.
Marco DuranteDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany.
Burkhard JakobDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metabolic differences of normal- and cancer cells represent an important target for the development of novel cancer treatment strategies. Given that radiotherapy constitutes one of the primary treatment modalities for solid cancers, the targeting of cancer cell metabolism to enhance their sensitivity to irradiation emerges as a promising approach. The utilization of glycolysis even under aerobic conditions in cancer cells presents a unique target to deprive cancer cells of energy and metabolites required not only for their rapid cell growth but also for the repair of irradiation induced DNA damage. Furthermore, cancer cells have been observed to exhibit elevated levels of reactive oxygen species and potentially react more sensitively to an induced disturbance of the redox balance, especially after irradiation mediated oxidative stress. Overall, interference with aerobic glycolysis and the oxidative stress response could potentiate the anti-proliferative and cytotoxic effects of cancer cell irradiation, while sparing normal cells. Methods: To analyze the effect of inhibitors targeting the cellular metabolism and redox balance, normal fibroblast- and cancer cell lines were characterized using a Seahorse XFp metabolic analyzer, followed by Sulforhodamin B proliferation assays and flow cytometry based cell cycle analysis. Furthermore, NADP+/NADPH-, NAD(P)H- and ROS levels were determined using bioluminescent assays, Fluorescence Lifetime Imaging Microscopy (FLIM) and fluorescent microscopy. Radiosensitization of cell lines was assessed through clonogenic survival assays and analyses of DNA-repair efficiency via fluorescence microscopy. Results: The present study demonstrates that the glycolytic inhibitor 2-deoxy-D-glucose and the NAD(P)H:quinone oxidoreductase inhibitor ES-936 can render cancer cells more sensitive to X-rays and densely ionizing radiation (high-linear energy transfer (LET) irradiation) like alpha-particles or heavy ions but do not affect normal fibroblasts. While inhibitor-treated and low-LET (X-ray) irradiated cancer cells exhibited a decreased clonal survival, an additional DNA repair defect was observed after high-LET irradiation. Discussion: Our results imply that distinct mechanisms influence the clonal survival and DNA repair of irradiated, inhibitor-treated cancer cells in dependence of the LET. The findings of this study suggest that the combination of inhibitors targeting glycolysis and the redox balance may represent a promising strategy to enhance the sensitivity of cancer cells to both photon- and charged particle therapy.

Indexed as

2-deoxy-D-glucosecancercarbon-ionsDNA-repairglycolysishigh-LETmetabolismradiotherapy

Identifiers

PMID40900796
PMCPMC12399609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.